impaired c-met receptor degradation mediated by met exon 14 mutations in non–small-cell lung cancer
Published 6 years ago • 3.4K plays • Length 2:51Download video MP4
Download video MP3
Similar videos
-
1:02
investigating met exon 14 mutations in patients with nsclc
-
3:40
metex14 sas (met exon 14 skipping alterations) in non-small cell lung cancer
-
3:24
impact of met inhibitors in met exon 14-mutant nsclc
-
6:21
intertumoral molecular heterogeneity of non-small cell lung cancer with met exon 14 skipping – d...
-
5:04
c-met role as biomarker and player in innate and acquired resistance in non-small-cell lung cancer
-
4:14
crizotinib in patients with advanced met exon 14-altered nsclc
-
1:17
updates on met targeted therapy for exon 14 mutations in lung cancer | oncotarget
-
0:58
vision trial produces positive data in nsclc with met exon 14 mutations
-
1:11
detecting the met exon 14 skipping mutations in nsclc
-
16:56
dr siddharth turkar -selection of 1st line therapy for met amplification and met exon 14 mutation in
-
1:37
dr. awad on acquired resistance to met inhibitors in nsclc
-
2:47
key points about met in lung cancer
-
2:49
the challenges of treating metex14 nsclc
-
6:13
vision: tepotinib in met exon 14 skipping nsclc
-
6:28
mechanism of met exon 14 skipping and met receptor stability in lung cancer
-
13:00
recognizing the role of capmatinib for metex14 in nsclc
-
1:36
met as a clinical target in lung cancer
-
49:28
met signaling in nsclc: challenges and opportunities for biomarker development and drug discovery
-
7:16
are met mutations now a mutation we should look for in lung cancer?